| Title | [Novel B-cell directed strategies for the treatment of rheumatic diseases.] | | Author(s) | Tarner IH | | Institution | Lehrstuhl für Innere Medizin mit Schwerpunkt Rheumatologie, Justus-Liebig-Universität Giessen, Abteilung für Rheumatologie und klinische Immunologie, Kerckhoff-Klinik, Benekestr. 2-8, 61231, Bad Nauheim, Deutschland, Ingo.H.Tarner@innere.med.uni-giessen.de. | | Source | Z Rheumatol 2009 Jun 5. | | Abstract | The clinical success of B-cell depletion using the anti-CD20 antibody rituximab has sparked a new era in the therapy of rheumatic diseases. A large variety of novel B-cell directed biologic agents has been developed recently. The new strategies not only aim at depleting B-cells (ocrelizumab, veltuzumab, ofatumumab, TRU-015) but also target essential survival and proliferation factors such as BAFF (belimumab, atacicept, briobacept), and are directed at modulating B-cell function via CD22 (epratuzumab), inhibition of costimulation (abatacept) and induction of tolerance (abetimus). Thus far, clinical trials indicate high efficacy comparable to rituximab as well as a good safety profile. This review summarizes the therapeutic mechanisms of the novel B-cell directed agents and the current status of clinical trials in rheumatic diseases. | | Language | GER | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19513729 |
|
